These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16276352)

  • 61. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era.
    Bianco FJ
    Urol Oncol; 2008; 26(4):408-14. PubMed ID: 18593619
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy.
    Bostancic C; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath R; Lief J; Gutman SE
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1431-7. PubMed ID: 17544597
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
    Morgunov LIu; Vertkin AL; Pushkar' DIu
    Urologiia; 2007; (5):49-51. PubMed ID: 18254226
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Role of androgen in the elderly. Problems of androgen deprivation therapy].
    Tsujimura A
    Clin Calcium; 2013 Aug; 23(8):1185-90. PubMed ID: 23892220
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.
    Shigehara K; Sugimoto K; Konaka H; Iijima M; Fukushima M; Maeda Y; Mizokami A; Koh E; Origasa H; Iwamoto T; Namiki M
    Aging Male; 2011 Mar; 14(1):53-8. PubMed ID: 21171937
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
    Johansen KL
    Semin Dial; 2004; 17(3):202-8. PubMed ID: 15144546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.